Literature DB >> 23928243

Breast magnetic resonance imaging for monitoring response to therapy.

Haydee Ojeda-Fournier1, Jade de Guzman, Nola Hylton.   

Abstract

There is no difference in disease-free or overall survival in patients who undergo adjuvant versus neoadjuvant chemotherapy. Thus, neoadjuvant chemotherapy is recommended in patients with locally advanced breast cancer who would like to consider breast conservation, and is also the primary treatment in patients with inflammatory breast cancer. Magnetic resonance has emerged as the most sensitive imaging modality to assess the response of tumor to neoadjuvant chemotherapy.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Breast conservation; Magnetic resonance imaging; Mammography; Neoadjuvant chemotherapy; Pathologic complete response; Response prediction; Ultrasound

Mesh:

Substances:

Year:  2013        PMID: 23928243     DOI: 10.1016/j.mric.2013.04.005

Source DB:  PubMed          Journal:  Magn Reson Imaging Clin N Am        ISSN: 1064-9689            Impact factor:   2.266


  2 in total

1.  Long-term follow-up of breast-conserving therapy in patients with inflammatory breast cancer treated with neoadjuvant chemotherapy.

Authors:  Valentina Bonev; Maristella Evangelista; Jeon-Hor Chen; Min-Ying Su; Karen Lane; Rita Mehta; John Butler; David Hsiang
Journal:  Am Surg       Date:  2014-10       Impact factor: 0.688

2.  Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.

Authors:  Savannah C Partridge; Zheng Zhang; David C Newitt; Jessica E Gibbs; Thomas L Chenevert; Mark A Rosen; Patrick J Bolan; Helga S Marques; Justin Romanoff; Lisa Cimino; Bonnie N Joe; Heidi R Umphrey; Haydee Ojeda-Fournier; Basak Dogan; Karen Oh; Hiroyuki Abe; Jennifer S Drukteinis; Laura J Esserman; Nola M Hylton
Journal:  Radiology       Date:  2018-09-04       Impact factor: 29.146

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.